2,253
-2.30%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alfresa Holdings
Its shares trade on Tokyo Stock Exchange under the ticker 2784.T. It has been listed since 29 September 2003. In the fiscal year to 31 March 2026, it reported revenue of ¥3.10trn and net income of ¥41.75bn. At that date it held total assets of ¥1.51trn and shareholders' equity of ¥507.36bn.
Alfresa Holdings Corp. engages in the management of its subsidiaries that deal with wholesaling, manufacturing, import, and export of pharmaceutical products, diagnostic reagents, and medical devices. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2003-09-29. The firm operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 29 Sept 2003
- Employees
- 12,074
- Website
- alfresa.com ↗
Leadership
Pay as last reported
- Mr. Ryuji ArakawaPresident, Representative Director, since 2007
- Mr. Hisashi KatsukiPresident of Subsidiary, Director, since 2017
- Mr. Koichi ShimadaChairman & President of Subsidiaries, Director, since 2018
- Mr. Seiichi KishidaVice President, Representative Director, since 2018
- Mr. Yusuke FukujinVice President, President of Subsidiary, Representative Director, since 2020
- Mr. Shigeki OhashiManaging Executive Officer, Senior Director of Group Medical Wholesale Business, Director, since 2020
- Mr. Toshiki TanakaManaging Executive Officer, Director, since 2022
- Mr. Kazuaki HanoExecutive Officer
- Mr. Soichi NemotoExecutive Officer
- Ms. Miki OguchiExecutive Officer
- Mr. Yoshihiko SanoExecutive Officer
- Mr. Takashi SasakiExecutive Officer, Director of Financial Planning
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 43
- Social
- 75
- Governance
- 45
- Direct emissions (scope 1)
- 32,904 t
- Energy emissions (scope 2)
- 38,939 t
- Women in the workforce
- 47.09978%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alfresa Holdings Corp has several strengths that contribute to its success in the market. Firstly, the company has a strong brand image and reputation, built over years of experience in the pharmaceutical industry. This solid reputation allows Alfresa Holdings Corp to gain the trust of customers and partners.
- Secondly, Alfresa Holdings Corp has a wide network of distribution channels, enabling it to reach a large customer base effectively. This extensive distribution network gives the company a competitive advantage in terms of market reach and penetration.
- Additionally, Alfresa Holdings Corp possesses a diverse product portfolio, offering a range of pharmaceutical and healthcare products to cater to the diverse needs of its customers. This product diversity helps the company attract and retain a broad customer base.
Weaknesses
- Despite its strengths, Alfresa Holdings Corp also faces some weaknesses that may hinder its progress. One notable weakness is the company's dependence on key suppliers for sourcing its products. Any disruptions in the supply chain or issues with these suppliers can negatively impact Alfresa Holdings Corp's operations.
- Furthermore, the company has limited international presence compared to some of its competitors. This lack of global reach may limit Alfresa Holdings Corp's growth opportunities and make it more susceptible to regional market fluctuations.
Opportunities
- Alfresa Holdings Corp has several opportunities to capitalize on. Firstly, the growing demand for pharmaceutical and healthcare products in emerging markets presents significant growth potential for the company. Expanding into these markets can help Alfresa Holdings Corp tap into new customer segments and increase its market share.
- Moreover, advancements in technology and digitalization offer opportunities for Alfresa Holdings Corp to enhance its distribution channels and improve operational efficiency. Investing in digital platforms and e-commerce can provide a competitive edge and streamline business processes.
Threats
- Alfresa Holdings Corp faces certain threats that it needs to navigate carefully. Firstly, intense competition in the pharmaceutical industry poses a threat to the company's market position. Competitors with larger market shares and greater resources can potentially outperform Alfresa Holdings Corp.
- Additionally, changing regulations and policies in the pharmaceutical sector can impact Alfresa Holdings Corp's business operations. Adapting to new regulatory requirements and complying with evolving standards may pose challenges and increase operational costs.
- Furthermore, economic downturns and market uncertainties can adversely affect Alfresa Holdings Corp's financial performance. Fluctuations in currency exchange rates, interest rates, and overall economic conditions can impact the company's profitability and business growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.